<SEC-DOCUMENT>0001372514-23-000010.txt : 20230207
<SEC-HEADER>0001372514-23-000010.hdr.sgml : 20230207
<ACCEPTANCE-DATETIME>20230207070156
ACCESSION NUMBER:		0001372514-23-000010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230207
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230207
DATE AS OF CHANGE:		20230207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		23592746

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kprx-20230207.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:b4b573b7-9bfc-4ba1-b8b5-dcea2a2e0e07,g:70deb569-374b-4fa5-84b1-b80d6dd040c6,d:d760589d10a142ec850423f46d4d1060--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20230207</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF80L2ZyYWc6MWY3ODIwNWJlNjEwNDYzZGJiZGQyM2FkMTMxYmUwMDgvdGFibGU6OWZiZTkyYmJjYTA0NDVkOWJiMGE0YjYzZTlmYmRhMTMvdGFibGVyYW5nZTo5ZmJlOTJiYmNhMDQ0NWQ5YmIwYTRiNjNlOWZiZGExM18yLTEtMS0xLTMzOTc_abaa7a83-3927-49e9-944b-d09c80e3a4a5">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF80L2ZyYWc6MWY3ODIwNWJlNjEwNDYzZGJiZGQyM2FkMTMxYmUwMDgvdGFibGU6OWZiZTkyYmJjYTA0NDVkOWJiMGE0YjYzZTlmYmRhMTMvdGFibGVyYW5nZTo5ZmJlOTJiYmNhMDQ0NWQ5YmIwYTRiNjNlOWZiZGExM18zLTEtMS0xLTMzOTc_df6e9172-e581-44f6-8942-ce8345357caf">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20230207.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id760589d10a142ec850423f46d4d1060_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE4_3a685335-1f15-415f-85e3-b032823c53d2">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8yMjI_f171e282-8611-4a80-a30c-a67027229d86">February 7, 2023</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE0_c83bd2e4-3fb5-4733-8b15-2d123ea12acb">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzA4_265ca302-56bb-4336-bafe-839e3660b69d">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.393%"><tr><td style="width:1.0%"></td><td style="width:42.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6MDM4MzA3NmZkZTYyNGJkZThiODI1NTFhOTg3OThiYmEvdGFibGVyYW5nZTowMzgzMDc2ZmRlNjI0YmRlOGI4MjU1MWE5ODc5OGJiYV8wLTAtMS0xLTMzOTc_951fc2f3-99d3-4ca0-933e-8106e3eea999">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6MDM4MzA3NmZkZTYyNGJkZThiODI1NTFhOTg3OThiYmEvdGFibGVyYW5nZTowMzgzMDc2ZmRlNjI0YmRlOGI4MjU1MWE5ODc5OGJiYV8wLTEtMS0xLTMzOTc_7efd7c20-0921-4a58-adfc-02ec8f091dc8">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xNjQ5MjY3NDQzMTgz_279abdea-0540-45d2-a7e0-626a1250486c">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzEy_3417a46d-d7a8-4ebf-98d6-307b0679fa65">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE1_a507bd77-9d09-49ef-92f9-447b9e57253b">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE2_a9a8a383-9cb3-4fe6-ba96-4dd1931f6d81">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV80MjA_0678b234-d3c2-43e5-a67f-2ed58da96cb8">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV80MjQ_f797fd94-f74b-4f6e-9974-317274470012">781</ix:nonNumeric>) <ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzIw_d4a1cae0-71de-410a-a36d-27b6c9b80ac4">788-9043</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N18wLTAtMS0xLTMzOTc_de7ea117-05c0-4891-9a12-9ed7fff949c6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N18yLTAtMS0xLTMzOTc_11f7d719-c49b-47aa-ba97-f7efee15a6ba">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N180LTAtMS0xLTMzOTc_79fe3507-aaf6-4780-ba64-28504cf3f3dd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N182LTAtMS0xLTMzOTc_979690c5-dac1-480a-831a-48b3b1c16115">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTAtMS0xLTMzOTc_ed9adefd-e08c-4b72-9363-0d3162df13d6">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTItMS0xLTMzOTc_7b29d764-7d4b-4103-a27b-678bcffa6689">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTQtMS0xLTMzOTc_f22e9c6e-d722-4cb1-bd5c-4ab176ee1532">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzEx_ebb2121f-2cdf-4df9-ab8b-1e38872c481b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#212529;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id760589d10a142ec850423f46d4d1060_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01.&#160;&#160;&#160;&#160;Other Events.</span></div><div style="margin-top:10pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing that it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis or other autoimmune diseases (OPRA+). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id760589d10a142ec850423f46d4d1060_10"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.28pt">Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-pressreleasekiox101p.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991-pressreleasekiox101p.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of February 7, 2023.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id760589d10a142ec850423f46d4d1060_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 7, 2023</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-pressreleasekiox101p.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1dcdf4ca80e04f5584700f44c9ee43e4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Kiora Pharmaceuticals Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases</font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encinitas, California &#8212; February 07, 2023 -- Kiora Pharmaceuticals, Inc. (NASDAQ&#58; KPRX), (&#34;Kiora&#34; or the &#34;Company&#34;) today announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease. The study is expected to begin enrolling patients in Australia in the first half of 2023. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Ocular surface disease is the most common non-joint manifestation of patients living with Rheumatoid Arthritis (RA) as well as other common autoimmune diseases,&#8221; said Eric Daniels, M.D., Chief Development Officer of Kiora. &#8220;While the systemic treatment of underlying autoimmune diseases has advanced dramatically in the past decade, these agents commonly do not address local ocular disease. This unfortunately leaves affected autoimmune patients with few available eye drug options that only offer limited relief in addressing the moderate to severe ocular dryness, pain and discomfort associated with these diseases. KIO-101 is a topical, patient-friendly eye drop with a proven mechanism of action in autoimmune diseases. Proof-of-concept has been established in previous ocular inflammation clinical studies for KIO-101. This drug has the potential to finally close the wide gap of untreated ocular disease in patients with common autoimmune diseases.&#34;</font></div><div style="margin-top:10pt"><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-101 is part of a class of non-steroidal autoimmune disease drugs called DHODH inhibitors, which reduce </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T-cell proliferation and ongoing proinflammatory cytokine release. Approved systemic drugs in this class, which target systemic disease, generate about $2B in annual revenue. KIO-101 has the potential to affect the local immune response in the eye responsible for the ophthalmic signs and symptoms of these autoimmune diseases. Of the autoimmune diseases that KIO-101 is targeting, the ocular manifestations </font><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are found in approximately 3.43M patients in the U.S.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2 study of KIO-101 is a </font><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multicenter, randomized, controlled, double-masked clinical trial in up to 120 patients with ocular signs and symptoms and diagnosed autoimmune diseases, including RA, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">psoriatic disease, systemic lupus erythematosus, or fibromyalgia</font><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The study will evaluate two concentrations of KIO-101, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.15 % and 0.30 %</font><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The efficacy endpoints will evaluate a number of established ocular signs and symptoms, including but not limited to corneal staining and changes in the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Schirmer's test score at 12 weeks. The study will also evaluate several safety and tolerability measures. </font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Kiora Pharmaceuticals</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and&#47;or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (&#34;OPRA&#34;). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (&#34;DHODH&#34;) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and&#47;or subscribe to email alerts.</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:10pt"><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the statements in this press release are &#34;forward-looking&#34; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &#34;forward-looking&#34; statements include but are not limited to statements relating to, among other things, results from the planned study or studies of KIO-101 that could support Kiora's efforts to advance KIO-101 to more advanced stages of clinical development, gaining regulatory approvals and commercialization, as well as the success thereof, with such approvals. Success may not be obtained or achieved on a </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &#34;Risk Factors&#34; contained in Kiora's Amendment No. 1 to Annual Report on Form 10-K&#47;A filed with the SEC on July 7, 2022 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact</font></div><div style="margin-top:2pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Francina Agosti, Ph.D.</font></div><div style="margin-top:2pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(617) 546-0742</font></div><div style="margin-top:2pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">fagosti&#64;reportablenews.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>kprx-20230207.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b4b573b7-9bfc-4ba1-b8b5-dcea2a2e0e07,g:70deb569-374b-4fa5-84b1-b80d6dd040c6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20230207" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20230207">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20230207_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20230207_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>kprx-20230207_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b4b573b7-9bfc-4ba1-b8b5-dcea2a2e0e07,g:70deb569-374b-4fa5-84b1-b80d6dd040c6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_f33f27d4-be0b-4422-a23c-3b13ca78a32c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_8c7551bb-3cd6-4b1f-81f5-cff6e4a845f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bf1e376a-3969-4f71-9404-3c4647269962_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8952328b-4fd8-47b9-9095-37665a8ff1f9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f2900f87-7097-4cc4-90ae-e1240c181b2b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cfd43f1c-867a-492f-9186-848efe6c690a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_498e10e6-bb56-4bc5-b67e-1091bf5e1468_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6951d816-f7d2-4269-abc8-63bc7e8dd2be_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8032cc89-80ba-4c9d-a796-52fcc3bba04a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_246f407b-2920-4f6f-a83d-1cd3d2f9bc7b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_51a9dd7f-a070-499f-89da-d89fa8686548_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ff205f92-5cb4-450a-95f8-07abb9df7c91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_af3ef838-1b2f-43d9-bab5-ee5ff3f6f614_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_88f87e2c-1940-4842-a0dc-9afde99a1fbf_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6630e6a2-8ad9-4a24-92e0-aedb1b533fef_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e5332535-75e1-480f-86b6-015d86b0e677_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_39f8e462-b2eb-4e55-a706-65b91aa9cea1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ab30501b-b2e8-4eab-9d26-dd837902b8d8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3004722e-5581-46df-95aa-61d9352f3d8e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2ce7561e-9ba2-44fd-b4d1-d6c6dc7d1872_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fb631960-c483-4d4e-9f90-5f032f183b06_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fa59e306-465a-4d9b-a768-7e39be3ba807_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_58d19f67-0133-496e-8928-c1bf8557f12b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>kprx-20230207_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b4b573b7-9bfc-4ba1-b8b5-dcea2a2e0e07,g:70deb569-374b-4fa5-84b1-b80d6dd040c6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20230207.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ebef08e5-1605-4bc1-b212-ed8b7a14d8cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_DocumentType_ebef08e5-1605-4bc1-b212-ed8b7a14d8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3a4d0339-9270-4167-839b-b40c0faa2b22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_DocumentPeriodEndDate_3a4d0339-9270-4167-839b-b40c0faa2b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7e74f5af-739c-4848-9330-da0907b89537" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityRegistrantName_7e74f5af-739c-4848-9330-da0907b89537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a800461f-7c7c-4584-825c-2b7881b7df59" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a800461f-7c7c-4584-825c-2b7881b7df59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c9868d5a-d318-4e84-a056-3e0d45aff0da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityTaxIdentificationNumber_c9868d5a-d318-4e84-a056-3e0d45aff0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e277d329-50aa-40d9-a6a1-71d2ec1e872c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityFileNumber_e277d329-50aa-40d9-a6a1-71d2ec1e872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_27391084-ce0d-44a6-92d6-dd417bca944d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityAddressAddressLine1_27391084-ce0d-44a6-92d6-dd417bca944d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_53581342-16ef-41cd-a8a3-15bd0abfaee6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityAddressAddressLine2_53581342-16ef-41cd-a8a3-15bd0abfaee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3d801e0e-c23a-4c64-8172-ceb3103dc57d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityAddressCityOrTown_3d801e0e-c23a-4c64-8172-ceb3103dc57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_db6721f2-9fb6-40fa-9944-d4d10116166c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityAddressStateOrProvince_db6721f2-9fb6-40fa-9944-d4d10116166c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e348bb5e-8cf7-4a31-aedd-84013ce11476" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityAddressPostalZipCode_e348bb5e-8cf7-4a31-aedd-84013ce11476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2efeb40b-8d39-4967-a842-67df34a1828c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_CityAreaCode_2efeb40b-8d39-4967-a842-67df34a1828c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bb0057f3-e05c-4af4-8ce0-3619bd8056fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_LocalPhoneNumber_bb0057f3-e05c-4af4-8ce0-3619bd8056fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_32d6a6d5-afdf-4d8a-8a09-529fdebff8dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_WrittenCommunications_32d6a6d5-afdf-4d8a-8a09-529fdebff8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a9f964f2-3eba-4307-bdea-28c75a4b8582" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_SolicitingMaterial_a9f964f2-3eba-4307-bdea-28c75a4b8582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0aa3bad7-9efe-4380-ba3b-3a5da1428d55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_PreCommencementTenderOffer_0aa3bad7-9efe-4380-ba3b-3a5da1428d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_86186ca5-9b26-4483-9aed-3c0cd77c19ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_86186ca5-9b26-4483-9aed-3c0cd77c19ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2b59e5a1-0986-4801-a2c2-cba02a1adcb5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_Security12bTitle_2b59e5a1-0986-4801-a2c2-cba02a1adcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2c84e10b-c4e0-47c4-82be-bbae24b4f7f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_TradingSymbol_2c84e10b-c4e0-47c4-82be-bbae24b4f7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0b749170-07fe-4aee-a070-0b820160922f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_SecurityExchangeName_0b749170-07fe-4aee-a070-0b820160922f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ad4efe17-6cfa-4d39-b0ac-4c3d8a9f2628" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityEmergingGrowthCompany_ad4efe17-6cfa-4d39-b0ac-4c3d8a9f2628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_17cd8715-e1fe-4d55-bc8c-62ae41cc10bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_EntityCentralIndexKey_17cd8715-e1fe-4d55-bc8c-62ae41cc10bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6913c595-e64f-4e01-814a-c08ea276c96d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c0d01d8-324a-45c3-9109-49c85dd52991" xlink:to="loc_dei_AmendmentFlag_6913c595-e64f-4e01-814a-c08ea276c96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139633891293328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  07,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">788-9043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>kprx-20230207_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20230207.xsd" xlink:type="simple"/>
    <context id="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF80L2ZyYWc6MWY3ODIwNWJlNjEwNDYzZGJiZGQyM2FkMTMxYmUwMDgvdGFibGU6OWZiZTkyYmJjYTA0NDVkOWJiMGE0YjYzZTlmYmRhMTMvdGFibGVyYW5nZTo5ZmJlOTJiYmNhMDQ0NWQ5YmIwYTRiNjNlOWZiZGExM18yLTEtMS0xLTMzOTc_abaa7a83-3927-49e9-944b-d09c80e3a4a5">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF80L2ZyYWc6MWY3ODIwNWJlNjEwNDYzZGJiZGQyM2FkMTMxYmUwMDgvdGFibGU6OWZiZTkyYmJjYTA0NDVkOWJiMGE0YjYzZTlmYmRhMTMvdGFibGVyYW5nZTo5ZmJlOTJiYmNhMDQ0NWQ5YmIwYTRiNjNlOWZiZGExM18zLTEtMS0xLTMzOTc_df6e9172-e581-44f6-8942-ce8345357caf">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE4_3a685335-1f15-415f-85e3-b032823c53d2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8yMjI_f171e282-8611-4a80-a30c-a67027229d86">2023-02-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE0_c83bd2e4-3fb5-4733-8b15-2d123ea12acb">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzA4_265ca302-56bb-4336-bafe-839e3660b69d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6MDM4MzA3NmZkZTYyNGJkZThiODI1NTFhOTg3OThiYmEvdGFibGVyYW5nZTowMzgzMDc2ZmRlNjI0YmRlOGI4MjU1MWE5ODc5OGJiYV8wLTAtMS0xLTMzOTc_951fc2f3-99d3-4ca0-933e-8106e3eea999">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6MDM4MzA3NmZkZTYyNGJkZThiODI1NTFhOTg3OThiYmEvdGFibGVyYW5nZTowMzgzMDc2ZmRlNjI0YmRlOGI4MjU1MWE5ODc5OGJiYV8wLTEtMS0xLTMzOTc_7efd7c20-0921-4a58-adfc-02ec8f091dc8">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xNjQ5MjY3NDQzMTgz_279abdea-0540-45d2-a7e0-626a1250486c">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzEy_3417a46d-d7a8-4ebf-98d6-307b0679fa65">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE1_a507bd77-9d09-49ef-92f9-447b9e57253b">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE2_a9a8a383-9cb3-4fe6-ba96-4dd1931f6d81">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV80MjA_0678b234-d3c2-43e5-a67f-2ed58da96cb8">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV80MjQ_f797fd94-f74b-4f6e-9974-317274470012">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzIw_d4a1cae0-71de-410a-a36d-27b6c9b80ac4">788-9043</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N18wLTAtMS0xLTMzOTc_de7ea117-05c0-4891-9a12-9ed7fff949c6">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N18yLTAtMS0xLTMzOTc_11f7d719-c49b-47aa-ba97-f7efee15a6ba">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N180LTAtMS0xLTMzOTc_79fe3507-aaf6-4780-ba64-28504cf3f3dd">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N182LTAtMS0xLTMzOTc_979690c5-dac1-480a-831a-48b3b1c16115">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTAtMS0xLTMzOTc_ed9adefd-e08c-4b72-9363-0d3162df13d6">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTItMS0xLTMzOTc_7b29d764-7d4b-4103-a27b-678bcffa6689">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTQtMS0xLTMzOTc_f22e9c6e-d722-4cb1-bd5c-4ab176ee1532">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzEx_ebb2121f-2cdf-4df9-ab8b-1e38872c481b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M7;7?B>\;1J;Y[G<A#>RE\],UH^ 2]@&XOY32?#3LAKKX'C+X&U!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  \.$=6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( #PX1U8>MT=.[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #PX1U:97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M/#A'5FS&#\I=!   &Q$  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #PX1U:?H!OPL0(  .(,   -
M          "  : ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ /#A'5I>*
MNQS     $P(   L              ( !? \  %]R96QS+RYR96QS4$L! A0#
M%     @ /#A'5JK$(A8S 0  (@(   \              ( !91   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( #PX1U8D'INBK0   /@!   :
M      "  <41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( #PX1U9ED'F2&0$  ,\#   3              "  :H2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kprx-20230207.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="kprx-20230207.htm">kprx-20230207.htm</File>
    <File>ex991-pressreleasekiox101p.htm</File>
    <File>kprx-20230207.xsd</File>
    <File>kprx-20230207_lab.xml</File>
    <File>kprx-20230207_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "kprx-20230207.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "kprx-20230207.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20230207_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20230207_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20230207.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20230207",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20230207.htm",
      "contextRef": "ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20230207.htm",
      "contextRef": "ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001372514-23-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-23-000010-xbrl.zip
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M4P[6*4Y0A:TK,F2O5:6?6OR70,@6 9IL%X2@JA2%BC-$@2O(:S+F,-0[XV<
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MJFC:RQ4"!!R5"!\Y/YI!^>8I@T)!Q+P=H#./XXW7_7FR&>+WQ+QI,ZR:K[E
M\P;-W6%W#9OHIBCYJ$9A<7QME4E[H0CB;K;9:B"NFE6%7+$MD;4FHB:'FB5@
M /H+1;,Y*MSW]P#==_8 =RX*1\$!"W7G+?XZKXU'ZW4TVCPB(V?RVM]]Y",O
M_L._F6UWKH@&1F!Q-WV9 LN.9+Z4*[?W>7YL\)F3WNN"1FR1=$AQ\ADR(\_;
MK-K*G87)%R@/VMV$**(7NI:\S5G*L4V!$,O:J75^('C!<>A]"0WS;.!/ZZ3I
M[._ R2@%LMV TVFQ=R<D#T";QI-[[I(:EEL3+!="L:MT#X+9&QR^>>]+S^HP
M-N%L"5JRYB*5,=<]D# N4TEX]<7'TV]9*.\8=RYI]:NP.@ 1C=E";F"S-N^G
MT#[A;N&=&0A.]FD8.U\J!@@(_(HP;W_4?\-%<DJ\J/-RB*D25OV]ADKAI?Z8
M/+F1L'-<4+"JHQQTLN%7@_6WK=/(C=SJ(Z'7[\VBU5IY($\8J*_Y+64_ -M"
M$>+'0.'FQ? M2/YX87$5$B^\9Y/MW%M0UQ"N;Z]OA"=^2+?I/:%V:$,T3QX!
MQ-"T*1ZP"?O*RYN [.LS@SWH1#Q15W0:)P.]UG+AY9\)X-<1GY]/<V*E]%B8
MYY!2VK>OP9O9&WL*8 P[!$"EML1VGEK/M.E-@W>]3@3RI#'6-JX+G(V,XQ .
MUJ<-MJ7B7@P:H4M0'_B5'?_6XK^UML&#N5S^Z8C4ZX9LBC-*H-A_BOSCAQ!_
M-\*^LI)^D2/%=([.1??$13:8?9(3OB EGGR[_^RI.)Q\VQ\]FXS_5,+_4B>6
M2O;)XT??3HXMXRUU]=2-=KO&+Y2Q#,.O)OGWFZ?_ U!+ P04    "  \.$=6
ML"SY&^03   ZA   $0   &MP<G@M,C R,S R,#<N:'1M[5WK5]NXMO\^?X5N
MYMXY=%V46/([M)R5DL"DK1T(H4SXPI(MF3@X<8[M0,)??[;LA'=H: N$EEFK
M0Q*]MK:V?MHOR^__/1E$Z$PD:1@//Y1(62FA?V^^_Q^,__G8_H+JL3\>B&&&
MMA+!,L'1>9CUT"$7Z2D*DGB #N/D-#QC&.=MMN+1- E/>AFB"E5O%2953_-T
M4_5,;'N!CS6/$>Q9GHZY+QAE5"A",==/JJ;"A:<;-E9-S<-:P'1L:9ZLJW"#
M<T53?&.=5[EI*+IE<Z(PHE'A6[JB4370#*[!;X8BA^UE,#N8X3"MAI,,I\+_
M4.IEV:A:J9R?GY?A>_DD/JN$PR@<"CGC2I:P81K$R8!EP)$*58B.%0NKI#3K
M9P)53V_T<JZ6X^2D0FS;KN2ELZJ+*TFR2I=TW:@W\9(HKPDCJ]<(FU>_,_JU
M!HI:D<4>2\6\.A?A9>V\YGS*4  M*+V<%A2&#W0<#M.,#7UQ179V?^V'>$D5
MK%!,K@9-P_N8! .2RC_.EWV_)P8,WQBZ&K'AR8>2&.*#_1(LL&!\\_U 9 S)
M?K#XSS@\^U#:BH<9B"WN3$?0S"^^?2AE8I)5<N97-O_XXX_W69A%8O-TE$RP
M%%B@SWQ?*7Y\7RFZ]F(^W7S/PS.49M-(?"CQ,!U%;%H=QD,!!(23JJPHDN)C
MR+D8YA^AW(6]DX1^,?XD:XO@0RGTB<FUP+<M5>,:]2T[T$&0@X#YL"D("8[K
M<U(N:2JA(1O(H458;0R!OND63"=A47/(Q>2SF)90R*%KKGZ=>O7X[ MMGW55
M9\S[C;.C';O?&NRI;K]&6O7HU.E\[#F=O>G1H:.YG9KB]-V!6S\Z=7?V)DZ]
M>_Y%=:/NQ>C4O>B>NYT3_:C>..]V&HHS^-IOU0_.W7KSXJB_1X_J;>BK1IUM
M2_E"CZ;=0]]P#KMJJ]X\=P\_16Z_ 76[%T<[G\*CG;VI0[>AOC/I#@[.G?K)
M&=_9#KV= Z-U>!0>=4ZGW<&G?A?H<>M?3UN'GT)GIZ%T^]"^$PVZ@S;0[,S:
M?(6Q].%1)]:/!I^B5N=3V!VX/:>^I[B'>WIWT 1ZVZ';=Z.\[YW&Q"'6]$NG
MD3G[RN1+Q[EH=?QCYC%F,DO%JDU-K-G"QK8&<,,5V[<4H3*-Z:5-!211-:E.
MM/>5&VOZE$M< \3E$G6W(W;RMK3?6MJ+VTO+ T/8Q*18Z!;!FA88V+(UBGT!
M"Z*KNNFSH+09L"@5=U:U<G,3)R(0B0#L2>_!'HFUU33'*%AWE$-_-0/$^5!*
MP\$HDH"5_]9+I%C<@)GR).701>5F'\7X5X/.:$CC<9)_RT&Z.I.U0C"^1];F
M'8D<2^;?0BZ_!Z%(4$Z0N/>HW&I^OKDM;C?>G/]TL_<1\#?F\V\ Z$E6!XUB
M4Q(E#P6)O+?++LGD"ZK.2^;?YX-4;C!JSM5+-E:N@78%H+W ]V*??4.I.":E
MZVUF9\(@'.*>D(I/5=-'V<9YR+->E2C*_Y7R>IOOTQ$#B?*2"K0N/A>=W.V*
M)2?06Q:/JM8H@^89\R(Q+_7B!*C&?AQ%;)2*ZOS#QOQ4*DY?G#?:F/7EQ5D6
M#ZJ2,%#TLM!G$691>#*L2N[,BJ]H+BL%W1EP)^/SD6?%Y;RHDO&[9;95MI7%
MQ4J97)95\KZ3>849Z]1BOAS -)(\^E!22[<F/IL*U$0\'DO&_ G4;HP8Y^'P
MI*H@DO=Q-4@EY\0W^;R1<Z)@B@^"*Y)2L6;SZD!2G%3_I(3JU-X(0+!PP 9A
M-*W^JQ,. !Y<<8[:\8 -_[6>@M8#JF82!D7%-+P052)'R;^>%[,U@>Y\K6:S
M)U3R[L!M=AIUM-^I=1K[-T7E&O&K0NU^8^N@W>PT&_NHYM91XY^MOVON3@-M
MM1RGN;_?;+DO. 5EJ2D<UO;_;KH[G9:[CNI;8+?HFKV0Z!45FNU6VT%/J)#,
MK<!"FWY)?60RUT= #XB<"^BO?TJ/.OP4])%S=]!06IVOI]W!'K2#\0Z/(M _
M0+?XJO&_/T5'-#KS^J.>NW-PX= N;76.(I>";M&OT6YG3W</V^%1W1V OC$Y
M&GR-6E^MB7/1T(Y59EBZJNJ8!& -:D0/L*4+%7N*2BVJ^KK*:6G3PI_OJA.K
M(DC+;0;8S>V&VT'MQFZKW4&[!^W]@YK;6?E-W&DA@*(.X TB*FJU$='7^#O4
MVD:=OQLK3_TU%+U$T-I61Y)/;%5;72'2[IV.U,A0'*!$C.(D0VOS[X*!3B;2
M#(DSZ5$JB@5_5T7S&;X$\Y\!-G=SK;11Z*HE5#A$H/M)5N7P"Q[ F#W9#',V
MQ5/@$Q;#WPMGITZ_>1P0DP@ 5&P9!.PV9BF8J8J/F6$JU*34YI8!AYWPDC%+
MILA<S[V,JXNYVDL+8.$K:HN3,)6NN,R%DM]+KN3YK1S[ENIQ*C2L!AZ<WZ:J
M8LN#DYQR0E7!" 5^EC8_-UOM&MK]N]9V:EN-@TYSJ_9E?QTUW:WRTC*V*AB\
MUI@P/\M%H8#BN0@@EJ)T)'QIJG,4#E&8I<CO@<4MDG>KLW5>'+N+K=,<^G$"
MQU3NO][/ *RWXO$P2Z9;,;^)Y#*T(#T7F1@E\9GLYW>#<-AJ->V8&KH/H$VQ
M;G@>UE35P!X+!+946ZB&H7B&S4%%$!$[9\D][K=5WU>Y$* X07'6$PGJCY,P
MY:$OY4-NM/"ZP"R[GY[=R6/99=56O\?'H]&R;9A+^7@>TZVNE2U5?8SK:)&?
M:.X)HJ.)] 7=A:H[W(E']\N2DO_W-.BE/ MZ;8>1@-X]V"VO$8F*(()3=S1
M%M4=')T>=;I3=^<3_.V%K7J3N)WM7JMSHK;@>W?0N!U$.'<N3BZ<ND^/!NW(
M[3>5+OQM[30UIW] G,.&WJK[>FOG4]C]:IU_Z=1N!!%LG00^#51LVUS%FL\4
M;*LJ !E1#*$*P6S;EHYP@@'63+H0R6;R_":J#XIJATV:LPB"GV/GF]PN+;<W
M@U^F"+CIRT"[3:41I5N8\<#'B@QF!(I-N&^5-FT+*YJF4NMN7/.ZX+Y&L+US
M<.<2O+85#P9A*K-<D,1%5 C8N]>Z3Q?,LMG>1XW!*(JGH)S<W%'(C<OO[J[N
M,@$2XP&=_[Z@UN-[>49 >Q[+H<9Y(M)T]N<+$$!>)9A]OSG@]O=TI]]5W?K>
MA=,YN3BFILT\+AA6=$W!FLXI9J90L$$-,,%U1;,,O[2IJA0UAGXX##,P53]&
M9WRA]?W,.RP7'/2C)LJO*-KT-Q-MYZ(Q/58U8C+-X)B;S,*:\ )L6]S JF)Z
MBF': 3/TTN;^. 1[D2@+%<0W(7Y)(=Z"CZT$5*[?SUG3(,=,!UGEIHEMKM@R
M!PY$F ;P23,]6^@FU56OM'F)QK=%>'TE9/A7%L_<V]1*=I/X+,P38'\W&:7'
MS&864RVPPWT/[/! 2(>B;6"-<V*K)#"X14J;6[65Q-=?639WXS1CT5$X*GSA
MOY-D LVU8SCC+8^J&N:J3[&F"ET&*@-,!=<M#B+J>]+0!CXNMK%?29QE[0EE
M2I[ M42PWU**]HX#TS8#;FLX*)YU,02V;5/#*C&I">>PHA!:VC0M<EN&WCUE
MPM>7V&?1;B\>OF;_\8\</,WS8ZXQXC.P3TW"!=:(PC!30=VGIF?XMF<IS-?D
MREC85K3ELQ!6)I)UE1;PUY\6)>9&BC(1B9%<=33,EWU=QK.BL?1^(09[%&2,
MBQ6.$B^8Z7:<P*+,@N%)'K6%KZPXQF".@0R #T\$1ZG4LE#$TGEZTO=,MC].
MLS"8OM!LMWK"/T593R V&B7Q* EEP-*+)\@347PN9RL+)4^0A3^C((SD\H8I
MK'4FAARXD,7 B,$XRMA0Q.,TFJ*496$:3/.6LP:Q!Y-E\[BG++B69#"&?H##
MP^F\+(@C&%RVD^'Q4+IAT^JJAD=_( >>E&UUN13X1V76ZV7+?%1F_7?XLB,1
MW.7-8SS9-1"U"!T,0XD2R-G_,5?V$YYNATF8@:C+B,!X./..IW>S.;PXCCP&
M<IO![GF5)V 1B7([VP.GSR/WHJD=U7WJUD]U=_ I='?<OG/A:*U.E[@[S:G;
M\6]'HHASV)VZ]$!U^CU)+XQS2KN#IM*ET/+B1'?[!TJWWR0NN1M!Y<(4C! 3
M*[JO8,VR";89H=@6W R"P-9LWRAM_O4GJ#O:QL^-GRZ6Y<N'<9X;EV="!Q.Y
M+G5H-$[2L81, -WV&$!.H_H,/B5N[@M_# U#H*/F9VB-F&AKNXU ILM0\=;I
M],"C-=8#C];<^_#,(ZJ^0<ZW(6<_CD(?UG%XXL!Q+*E^PYL?Q)OI;;R!53"Y
M26SL:S:84B9CTE-D@F4E B&(S@R//3O>O 347 D;&LRD[2[.$(UA0J]!36-2
M:,$W@48#Y2*O>4_H^ UE5@QE=A,AE1KYZ'#^N)94YY-6$$@#_@UM?@AME-MH
M8]J!4'58",8" ]#&4@!M# U3^<2P'ZB!ROEO@38@=-B_)G7?U'"(QC%=\]XM
MASU%W3?T>77HTTS3L4C>,.CG81"]DZ-JVH:M^#KFS"=@82D,6RIA\,E3/>(3
M@Q#]#8/NQ2!58&W-7PZ#9G6_,WENI;R#U^S)PETG$L%OL =JY$X]DD/TS'T'
M+/D5O76J7:;*<H\=/*Y,4XR?[@0D9EFQOI>@YR8VYZSV(@]T%,+Q0HGR'7EW
M6/&PL]]#?L32:V[N1^H<OP0_$I9'C_:G R^.UM+'Y%O_<LQP9T]CYK(AYL<-
M8.UY+X1?K@"Y^I@D_!G 2O@%%J 4C'^.YI-Y1;GK3^E]*TZ]*:%>OD%?LZI9
M_SAP:7/:A3;NH:3E!.J=GH/J29V^ _^D*MGNNQ=W5$W%V>FJW?ZG4*JC70JJ
M9MT=M#HUJ-^=.A==J9Y.W1U'!55S<EO5%-QF7 0<"\625W>:%-NJH6*%J\2@
M/" J-TJ;4O\'>=[/8O]T'?TO',P$C5B"SE@T7ORPYT^!@K=M\,UM, /C HO?
M]L 2>Z!YT^7C49N;AH9A%3R9$:)B1DT/RT0P'U;!,"R[M/EYM_W/FZBO".+/
MC;I7>_/%<TO\W@V)#R@5MF\(S$U*L>;+2YBY#OC//&(:,JBB4M!K:OOUVMZW
M'R1\==9R<\BE"T$@;XK\/*\&*#T%=4WD#__?2GH)4P0D"IC]B51Y3Y+X/.M)
M3\1()L*P%,'Y"4/DMVX4H5Y%GQO8M^*\\"NQ516M_?4G,<R-/-P[KQSF]W6,
MY'T=,IM)]B1K*1N@W6!Z3X<W'!M%S]IES]*_<=7N6M_E5Y?YU%C ^4<F8R_K
M;Z5+$?7DV=CS6>_DD]XJYOPKNEI_Z#F"R;'P/)! $F#J\P!K/+ Q\RP/$Z%:
MEDE]S2+>-WVECQ&A'Y.;Q8]HK>KV:P8/P)_,)+T72\,[N8,]0$H1"5^^;6 8
MYS[)<2KR6C#568:BO%@^S/V4Q96_4M[SL:*I'#Q_2X'<^T.8&Y0DXBQ,H1W@
M+QOZ<G\SWY<W^<C*\G)YSA*>%KF)?)%#5%UCEP[1ZYA:?NS]=8<PJM31TA]C
M>/Q#(O)JG+2OZUKAZ[= C^)"1JN)B%@6GHD[]T)?D9&/KUPU81ZH]>/L;I-O
M727]V/NLS<O[K'O)E2UR(K"7"':*60#*0)5%YVR:EBK/<.EU+OS+@MJ3/TS5
MS,0 666%E L=Z^[_6[DJV)!76J9+Z4QRY!>"Z-80W;X]<1U]#N.$H=T> X7!
M%^-\'Z?KJ#GTRVA-8IU\/( J&S/5(O]&-MZ!NIN. 2H9H*9(93@I$@QPF@V'
M *R^!-:LQT K+A ]$;Z '2"5WS,!*UJDC@,02X3FR?A$IJM'\ZLJ\M3U,RB5
ML)X3!SU38->8YRGEGYLM3!22%TL2,_EVFCSP-\/GEC^.6()V@33X]3)-O=T3
M8U"+8K"7:TG6DPIR>G69%QM#B8P;"@2X)V>3HK76;KOV_^_*J ;P,;K,9[\Y
M9ZGY9QF#8XTCZ$C J<&DWMT+/9B^;9<)L(47.?;S^\%F5<$6@ /Q\L;_Q1*T
M<$LLNH!CR>OLE=(]@TF5$<. "?.S:CH>@/A.-U9[D]H/;=+MRW,_?Z)62DJ:
M+\ELC9;?N?,S <L >)6H9?U>3A0_@<X#(U5Q4>V%N+/&WSU2/_F)P]]B5YGF
M$>)'<_U5Z2MEV_B^1T">/TQKF66J/G68]KY4D6>*PRUP%!3B5T!#CI[%4X[/
M%IM<)8Y<A:V72+$CY-NZ],-NZ>]-P/M90SZ1&"]ZK$02$@1/)LL%?5SXLQM'
MJWDZDZP%-+%[3W-1"/_&BQ.(BK<BB8EM$YSK4S-UZC2,)Z#<C<J]#%@KM:?W
M%7;;@GC1+?H2JZVL^FH_3."2J[V;Z]7MF5XM-?W%ULDZXKD:#:HV5+QMV)07
M",W]P&8_8>[PZT@S_JGG"5&T%SU,!R'GD7BAR6_%0 W:92<"Q#03<A^"Y8OJ
M+&/%U9-K K0-SF=O4P4+4%J4S5QC1?E;5_GLQ1'7@C"_H.>)J"ON>GK9E\(T
M=]Q:YZ#]P%O OFV0WS!#5>/%'$^[U_SIA;O_/^,PF=GART4LU_-*[9MQ CZ.
MILAG8^G;SZ.7LW?.P# >&(O "2B(BY<<>*+'HD!Z6V1'^<DTJR"=/V(\A$9Y
M?VR<]>($9L=_2?M4T\N68?]T4Y*6;?OGWWR@F65+6\YB7O+L7'C8&*M\S-Z?
M4/K@&TN^;<SI*Z7TK#9USZ_#O)SV]G'ZF)SUV710_E=9Y7E5T@KZF(0PL%-&
M^QF</^M@693K]VZ6YQ6]QZ3TO0).KRB77Q\CI3V<OUHYCU9L]4(1@'8$FE)N
M4K2"(/1O^2U_;33][D/Z1=VK\KU_U3L>BM=GVU6\F$_A3R\;1)O_!5!+ P04
M    "  \.$=6G_&_\&P"  !]!P  $0   &MP<G@M,C R,S R,#<N>'-DS55;
M;YLP%'[/K_!XGKDE:1K4I-):59J4;5+6JGV;C'T@5L!FMFGHOQ]V0"EINS;2
M'L8+YISO._=C+BZ;LD"/H#278N%%?N@A$%0R+O*%=W=[@\^]R^5H=/$)XX<O
MZQ6ZEK0N01ATI8 88&C'S0;=,]!;E"E9HGNIMOR18+QTI"M9/2F>;PR*PWA\
MK%5).DFGLW$ZP_,THWB2D@BGY^D4,PHD)C&$$,X^Y\DL9)!.S^9X/)ND>)*1
M*3Z?I!8;LC/&PDE(SYS11B>:;J DJ$U,Z*31"V]C3)4$P6ZW\W=C7ZH\B,,P
M"AZ^K7XZJ-=A"RZV W23JJ+'CP.K3HF&'KZM5#. PQ/D;4VJ#5$E\:DL YMS
M&(<S#Q%C%$]K S=2E=>0D;HP"Z\6OVM2\(P#:^M>@*WL /!,;8C*P7PG)>B*
M4/BHY^4((5L57E92&21>Y7=EB>;S>=#8/#VTK^)*4F+<:+Q9%H?']HBC&(\C
MO]',"S[D=FB("VV(H'"*[_8+][Q_$<.AQZ?%T/-.C\$9TT#]7#X&#+CM7/RZ
M>_T6W!ZP/0Q]$B&D<7PKZ615Q44F]X)69 -/^NC7D/5K\V(77AD1]TJ(HDH6
M[\Q34"E9@3(<]/,]<@8V"K*%9[<)]U/[JR"IWT;20UXX&+; JH.6 L7JD$G/
M-4]5R]5M PK8U^9_3KQ2<&KB+46W]X9K](GY6_YMJT><+;PKV?X'/&1E=^NO
M[]POSO.>T9OLC3+(N.!N[$+W1 @?_AL8.=9%<(P]LE)K8#_$TIV/,^S('>0O
M1$H*6A>G\PYAO4GKA'T%NPT+ABNV_WZVADZPW^WEZ ]02P,$%     @ /#A'
M5G:JB'J,"@  $6$  !4   !K<')X+3(P,C,P,C W7VQA8BYX;6S57%UOVSH2
M?>^OT&9?=H&R%BF)(HLV%]W<=E%L;ELT*7JQBX7!ST2H+06RTB3_?BG93BR;
MLD4I5K4OK6*/AF>.>(;CH:0WO]W/9]Y/E2^2+'U[ E_Y)YY*12:3].KMR;?+
M#X"<_';ZXL6;OP#PYS^^GGN_9^)VKM+".\L5*Y3T[I+BVOLNU>*'I_-L[GW/
M\A_)3P; :77267;SD"=7UX6'?!1L?YN_YB&/XH#'@'(M0,@9!)SP"$BA&&)(
M^<J/7UZ]CGVI>(0I".*0@U"S")"0E[:^Q%+ZH2]PY726I#]>E_]PME">"2Y=
M5'^^/;DNBIO7D\G=W=VK>Y[/7F7YU03Y?C!96Y^LS.]W[.^"RAI22B?5MX^F
MB\1F:-S"R9]_G%^(:S5G($D7!4M%.< B>;VH/CS/!"LJS@_B\AHMRK_ V@R4
M'P&(0 !?W2_DR>D+SUO2D6<S]55IK_S_V]>/C4/226DQ2=55>66_J#S)Y$7!
M\N*<<34SZ"MOQ<.->GNR2.8W,[7^[#I7VNYVEN<UKR5*6J*$N$3YUZ;!)CW@
M/Q/>8A?K,X"KPOWT7!CW<?KIV>!>FOR@C@]X8YC>D)<3ZGTJAYJ[CT/UAGY\
MQ,\U+;*"S0:8%D_#;$">E1^<FZ/5,*6C/<FT&F>5NC>@JOM"I5(MLV7-M9?(
MMR?F:"I5,GV?%DGQ<&;6O9S-/IH3[O^E'J8Z"#2*90BX\LVB%"($& H$"#@,
M!(L)"Y"8%H^3>JI2\.UB/7XUR($13AQB*QHTFJM%=IN+I]5M/K,M66:U*M<W
M,DG97"UNV.H$ [,L!);(3Y<@O15*KX+I&9QO)D\A=2%R=GQZ9B-C)A,U++.R
M',CR[>@S<3CZ)WTM#/ J](42KZZRGQ-SKJ$ H?( E >5K)H]3G8NWKM\C9/E
MX@#/*XN)R$RM<U. &N5E;=@RH")K>=V7U)EA3[PLERHW]:LE!,O\>R>EN?B+
MU7\FB2@T)2*.(L@Y"(3$IA"%&A"H(R"TQBID)(RT[R9FRR@C%?0*XLOU@5>"
M]2[O,E=AVXAM*^Z>= TC<'>F.@A]#Q,]Q&[S.K#@]P2V*_I]QEV%?\GN/TJ3
M3!*=+']^?;J=<Y5/N88JB#$# 36_,4,=0T!#/S2Y(,1AC#"E&+F)OV&DD28
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MZ'"2=W/4G01M<3>8A)M#V13M'JN>+:XS<_@YO\SNTBGQ R0$H8#XW-3>@DK
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M253S--PLL@50FT96@PZ;GDK<FG7@ 2)^F10S-<4X\!5F"!!FZJV0H1!0I'S
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MDP?=C_Z$^Y&>;1_#4^UNS[.[/,F^>27.S='IB_4GR?(=^J<O_@=02P,$%
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M2P$"% ,4    "  \.$=6G_&_\&P"  !]!P  $0              @ $'(0
M:W!R>"TR,#(S,#(P-RYX<V102P$"% ,4    "  \.$=6=JJ(>HP*   180
M%0              @ &B(P  :W!R>"TR,#(S,#(P-U]L86(N>&UL4$L! A0#
M%     @ /#A'5KP2BM_7!@   #,  !4              ( !82X  &MP<G@M
F,C R,S R,#=?<')E+GAM;%!+!08     !0 % % !  !K-0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
